Business Context and Reporting Period
Apogee Therapeutics, Inc. (APGE) filed a Form 8-K on March 10, 2025, reporting the entry into a Material Definitive Agreement. The Company is an emerging growth company incorporated in Delaware, focused on clinical development and potential commercial sale of its drug substance, APG777.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new contractual agreement.
Material Changes and Agreements
On March 10, 2025, Apogee entered into a Master Services Agreement (MSA) and an Initial Project Specific Agreement (PSA) with Samsung Biologics Co., Ltd., effective February 28, 2025.
- Scope: Samsung will manufacture and supply APG777 drug substance for clinical development and commercial sale at its Incheon, South Korea facility.
- Cost Structure: Apogee is obligated to pay service fees per batch, material costs, and expenses for testing and storage, detailed in Project Specific Agreements.
- Commitments: The Initial PSA requires minimum quantity purchases for clinical batches. A separate PSA for commercial supply is required, covering minimum purchase commitments for each year from 2029 to 2034.
- Exit Fees: If Apogee elects not to enter the commercial supply PSA, it will incur an exit fee in the high single-digit millions.
- Termination: The MSA terminates in February 2035; the Initial PSA terminates in December 2034. Termination without cause generally requires Apogee to pay the aggregate product commitment for the remainder of the term.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future performance. Key risks and contingencies identified include:
- Financial Liability: Significant potential costs associated with termination without cause or failure to execute the commercial supply PSA.
- Operational Dependency: Reliance on Samsung Biologics for manufacturing, process characterization, and validation.
- Force Majeure: Either party may terminate in the event of insolvency or inability to perform due to force majeure.
Investor Verification Checklist
- Verify the specific dollar amount of the "high single digit millions" exit fee in the full text of the MSA and PSA.
- Review the detailed minimum purchase quantities and pricing schedules in the Project Specific Agreements.
- Confirm the timeline for the filing of the full MSA and Initial PSA as exhibits to the Form 10-Q for the quarter ended March 31, 2025.
- Assess the impact of the 2029-2034 commercial supply commitments on future cash flow projections.